0000899243-22-026486.txt : 20220721
0000899243-22-026486.hdr.sgml : 20220721
20220721164841
ACCESSION NUMBER: 0000899243-22-026486
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220719
FILED AS OF DATE: 20220721
DATE AS OF CHANGE: 20220721
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ALTSHULER DAVID
CENTRAL INDEX KEY: 0001550395
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 221097572
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-07-19
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001550395
ALTSHULER DAVID
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP, Global Research and CSO
Common Stock
2022-07-19
4
M
0
10427
187.53
A
46604
D
Common Stock
2022-07-19
4
M
0
7338
155.57
A
53942
D
Common Stock
2022-07-19
4
S
0
963
286.72
D
52979
D
Common Stock
2022-07-19
4
S
0
4561
287.83
D
48418
D
Common Stock
2022-07-19
4
S
0
5737
288.67
D
42681
D
Common Stock
2022-07-19
4
S
0
6604
289.48
D
36077
D
Stock Option (Right to Buy)
187.53
2022-07-19
4
M
0
10427
0.00
D
2029-02-05
Common Stock
10427
3911
D
Stock Option (Right to Buy)
155.57
2022-07-19
4
M
0
7338
0.00
D
2028-02-05
Common Stock
7338
0
D
Includes 100 shares previously purchased under the issuer's Employee Stock Purchase Plan.
Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1.
Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $286.72 (range $286.07 to $287.01).
Open market sales reported on this line occurred at a weighted average price of $287.83 (range $287.11 to $288.10).
Open market sales reported on this line occurred at a weighted average price of $288.67 (range $288.11 to $289.09).
Open market sales reported on this line occurred at a weighted average price of $289.48 (range $289.11 to $290.06).
The option vests in 16 quarterly installments from 2/6/2019.
Fully vested.
/s/ Joy Liu, Attorney-in-Fact
2022-07-21